Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ACT042
MIFTS: 46

Acute Pyelonephritis

Categories: Nephrological diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Acute Pyelonephritis

About this section

MalaCards integrated aliases for Acute Pyelonephritis:

Name: Acute Pyelonephritis 12 54 15 71

Classifications:

MalaCards categories:
Anatomical: Nephrological diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:559
ICD9CM 34 590.1
NCIt 49 C123215
SNOMED-CT 67 36689008
ICD10 32 N10
UMLS 71 C0520575
Sources

Summaries for Acute Pyelonephritis

About this section
MalaCards based summary : Acute Pyelonephritis is related to acute kidney failure and bacteriuria. An important gene associated with Acute Pyelonephritis is CRP (C-Reactive Protein), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs leucovorin and Sulfamethoxazole have been mentioned in the context of this disorder. Affiliated tissues include kidney, testes and neutrophil, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Sources

Related Diseases for Acute Pyelonephritis

About this section

Diseases in the Pyelonephritis family:

Chronic Pyelonephritis Acute Pyelonephritis

Diseases related to Acute Pyelonephritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 714)
# Related Disease Score Top Affiliating Genes
1 acute kidney failure 30.9 LCN2 GPT ALB
2 bacteriuria 30.8 IL6 CXCR2 CXCR1 CXCL8 CRP ALB
3 hydronephrosis 30.8 NAGLU IL6 CXCL8 CRP ALB
4 prostatitis 30.8 IL6 IL10 CXCL8
5 pyuria 30.6 LCN2 IL6 GPT CXCL8 CRP ALB
6 cystitis 30.6 IL6 IL1A CXCL8 CXCL10 CRP
7 urinary tract obstruction 30.5 NAGLU LCN2 CRP ALB ACE
8 diverticulitis 30.5 IL6 CRP ALB
9 neutrophil migration 30.5 CXCR2 CXCR1 CXCL8
10 end stage renal disease 30.5 IL6 CRP ALB ACE
11 vesicoureteral reflux 1 30.4 NAGLU LCN2 CXCR1 CXCL8 CRP ALB
12 chronic pyelonephritis 30.4 CRP CALCA ALB ACE
13 splenic abscess 30.4 GPT CRP ALB
14 interstitial nephritis 30.4 CRP ALB ACE
15 acute cystitis 30.4 LCN2 IL6 IL10 GPT CXCL8 CRP
16 epidemic typhus 30.4 IL10 GPT CRP
17 urethritis 30.4 IL6 CXCL8 CRP
18 disseminated intravascular coagulation 30.3 IL6 IL10 GPT CRP
19 toxic shock syndrome 30.2 IL6 IL10 IFNG CXCL8 CRP
20 aortic aneurysm, familial abdominal, 1 30.2 IL6 CRP ACE
21 analbuminemia 30.2 GPT CRP ALB
22 thyroiditis 30.2 IL6 IL10 CALCA
23 neutrophilia, hereditary 30.1 IL6 CSF3 CRP
24 obstructive nephropathy 30.1 LCN2 ALB ACE
25 vasculitis 30.1 LCN2 IL6 IL10 CRP
26 glomerular disease 30.1 ALB ACE
27 cholelithiasis 30.0 GPT CRP ALB
28 acute kidney tubular necrosis 30.0 NAGLU LCN2 IL6 ALB ACE
29 membranous nephropathy 29.9 LCN2 ALB ACE
30 bacterial sepsis 29.8 IL6 IL10 CXCL8 CRP CALCA
31 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 29.8 CSF3 CRP ALB
32 anuria 29.8 LCN2 GPT CRP ALB ACE
33 acute cholangitis 29.8 IL6 GPT CRP CALCA ALB
34 pyelitis 29.8 LCN2 IL6 CXCR1 CXCL8 CRP ALB
35 hepatorenal syndrome 29.7 LCN2 GPT ALB ACE
36 vaginitis 29.7 IL6 IL1A IL10 CXCL8
37 deficiency anemia 29.6 LCN2 IL6 CRP ALB ACE
38 pelvic inflammatory disease 29.5 LCN2 IFNG CRP
39 atrial fibrillation 29.5 IL6 CRP ALB ACE
40 skeletal tuberculosis 29.5 IFNG CRP
41 cholangitis 29.5 IL6 IL10 GPT CXCL8 CRP ALB
42 sickle cell anemia 29.4 IL6 CXCL8 CSF3 CRP ALB
43 liver disease 29.4 IL6 IL1A GPT CXCL8 ALB
44 kidney disease 29.4 NAMPT NAGLU LCN2 IL6 CRP ALB
45 kawasaki disease 29.4 IL6 IL10 GPT CRP ALB ADM
46 scrub typhus 29.4 LCN2 IL10 IFNG GPT CRP
47 chronic kidney disease 29.4 LCN2 IL6 IL10 CRP ALB ADM
48 adult respiratory distress syndrome 29.3 IL6 IL10 CXCL8 CSF3 CALCA ACE
49 candidiasis 29.3 IL6 IL10 IFNG CXCL8
50 septic arthritis 29.2 IL6 IFNG CXCL8 CRP CALCA

Graphical network of the top 20 diseases related to Acute Pyelonephritis:



Diseases related to Acute Pyelonephritis
Sources

Symptoms & Phenotypes for Acute Pyelonephritis

About this section

GenomeRNAi Phenotypes related to Acute Pyelonephritis according to GeneCards Suite gene sharing:

26 (show all 27)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-100 9.77 NAMPT
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 9.77 NAMPT
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 9.77 NAMPT
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-120 9.77 NAMPT
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-128 9.77 IL10
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-132 9.77 IL10
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-142 9.77 NAMPT
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 9.77 NAMPT
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-164 9.77 NAMPT
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-166 9.77 NAMPT
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-169 9.77 NAMPT
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-17 9.77 NAMPT
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 9.77 IL10
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 9.77 IL10
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 9.77 CRP
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 9.77 NAMPT
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-202 9.77 NAMPT
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-204 9.77 NAMPT
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-25 9.77 IL10
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.77 IL10
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-49 9.77 CRP
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-50 9.77 NAMPT
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-57 9.77 NAMPT
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.77 CRP NAMPT
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-69 9.77 NAMPT
26 Decreased shRNA abundance (Z-score < -2) GR00366-A-80 9.77 IL10
27 Decreased shRNA abundance (Z-score < -2) GR00366-A-89 9.77 CRP

MGI Mouse Phenotypes related to Acute Pyelonephritis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.28 ACE ADM ALB CRP CXCL10 CXCR2
2 hematopoietic system MP:0005397 10.22 ACE ADM CSF3 CXCL10 CXCR1 CXCR2
3 homeostasis/metabolism MP:0005376 10.21 ACE ADM ALB CRP CXCL10 CXCR1
4 immune system MP:0005387 10.2 ACE ADM ALB CRP CSF3 CXCL10
5 integument MP:0010771 9.91 ADM CSF3 IFNG IL10 IL1A IL6
6 liver/biliary system MP:0005370 9.81 ACE ADM ALB CXCR2 IFNG IL10
7 neoplasm MP:0002006 9.56 ACE ALB CXCR2 IFNG IL10 IL1A
8 renal/urinary system MP:0005367 9.28 ACE ADM ALB CSF3 CXCR2 IFNG
Sources

Drugs & Therapeutics for Acute Pyelonephritis

About this section

Drugs for Acute Pyelonephritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 95)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
leucovorin Approved Phase 4 58-05-9 6006 143
2
Sulfamethoxazole Approved Phase 4 723-46-6 5329
3
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
4
Ceftriaxone Approved Phase 4 73384-59-5 5361919 5479530
5
Cefixime Approved, Investigational Phase 4 79350-37-1 5362065 54362
6
Nitrofurantoin Approved, Vet_approved Phase 4 67-20-9 5353830
7
Acetaminophen Approved Phase 4 103-90-2 1983
8
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
9
Ofloxacin Approved Phase 4 82419-36-1 4583
10
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
11 Fluoroquinolones Phase 4
12 Vitamin B Complex Phase 4
13 Folic Acid Antagonists Phase 4
14 Antiprotozoal Agents Phase 4
15 Folate Phase 4
16 Antiparasitic Agents Phase 4
17 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4
18 Vitamin B9 Phase 4
19 Antimalarials Phase 4
20 Antitubercular Agents Phase 4
21 Lactams Phase 4
22 Analgesics, Non-Narcotic Phase 4
23 Analgesics Phase 4
24 Antipyretics Phase 4
25 Cytochrome P-450 Enzyme Inhibitors Phase 4
26 Anti-Infective Agents Phase 4
27 Anti-Bacterial Agents Phase 4
28
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
29
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
30
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
31
Epinephrine Approved, Vet_approved Phase 3 51-43-4 5816
32
Racepinephrine Approved Phase 3 329-65-7 838
33 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
34
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
35
Ertapenem Approved, Investigational Phase 3 153832-46-3 150610
36
Doripenem Approved, Investigational Phase 3 148016-81-3 73303
37
Ceftazidime Approved Phase 3 72558-82-8, 78439-06-2 5481173
38
Avibactam Approved Phase 3 1192500-31-4
39
Sulbactam Approved Phase 3 68373-14-8
40
Vaborbactam Approved, Investigational Phase 3 1360457-46-0
41
Piperacillin Approved Phase 3 66258-76-2 43672
42
Colistin Approved Phase 3 1264-72-8, 1066-17-7 5311054
43
Tigecycline Approved Phase 3 220620-09-7 5282044
44
Fosfomycin Approved Phase 2, Phase 3 23155-02-4 446987
45
Edetic Acid Approved, Vet_approved Phase 3 60-00-4, 62-33-9 6049
46
Pentetic acid Approved Phase 3 67-43-6
47
Clarithromycin Approved Phase 3 81103-11-9 84029
48
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
49
Meropenem Approved, Investigational Phase 3 96036-03-2, 119478-56-7 441130 64778
50
Tazobactam Approved Phase 3 89786-04-9 123630

Interventional clinical trials:

(show all 49)
# Name Status NCT ID Phase Drugs
1 Impact on the Intestinal Microbiota of Treatment With Ceftriaxone in Women's Acute Community Pyelonephritis Unknown status NCT03179384 Phase 4 Ceftriaxone
2 Treatment of Acute Pyelonephritis With Gram Negative Strains in Infants and Children Less Than 3 Years Old. Cefixime PO 10d vs Ceftriaxone IV 4d Followed by Cefixime PO 6d. Multicenter, Randomised Trial of Equivalence. Completed NCT00136656 Phase 4 antibiotic;antibiotics
3 Relevance of Biomarkers and Clinical Predictors of Outcome in Unselected Population With Febrile Urinary Tract Infection at Primary Care and Emergency Department in a Prospective, Randomized Cohort Trial Comparing Short (7 Days) Antibiotic Treatment With Conventional Treatment (14 Days) Completed NCT00809913 Phase 4 short treatment (ciprofloxacin)
4 Randomized Controled Multicentric Trial, of Non Inferiority, Comparing Two Durations of Antibiotherapy (5 Days Versus 10 Days) in COMMUNAUTARY Acute Uncomplicated Pyelonephritis. Completed NCT00873626 Phase 4 levofloxacin, ciprofloxacin and ofloxacin (fluoroquinolones)
5 Antibiotic Prophylaxis After Acute Pyelonephritis for Prevention of Urinary Tract Infections in Children With Vesico-Ureteral Reflux. Completed NCT00382343 Phase 4 Sulfamethoxazole/trimethoprim
6 A Double-blind, Randomized, Placebo-controlled Phase IV Clinical Study of the Efficacy and Safety of a New Formulation of Paracetamol for the Management of Fever of Infectious Origin Completed NCT02283203 Phase 4 APOTEL max;Placebo
7 TREATMENT OF ACUTE UNCOMPLICATED PYELONEPHRITIS WITH SHORT COURSE LEVOFLOXACIN A Pilot Study Terminated NCT00239161 Phase 4 Levofloxacin
8 The Effect of L-carnitine on the Prevention of Renal Scarring in Children With Acute Pyelonephritis Unknown status NCT02007889 Phase 3 L-carnitine
9 Oral Omega-3 for Reduction of Kidney Scar Due to Pyelonephritis in Children Unknown status NCT02192580 Phase 3 Omega-3
10 To Study the Effect of Adjunctive Oral Methylprednisolone Therapy in Pediatric Urinary Tract Infection Unknown status NCT02331862 Phase 3 Methylprednisolone
11 A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Prospective Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) Completed NCT03788967 Phase 3 Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr);Ertapenem
12 A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Therapy in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis, With a Gram Negative Pathogen in Hospitalized Adults Completed NCT01599806 Phase 3 Ceftazidime - Avibactam ( CAZ-AVI);Doripenem;Either switch to oral therapy: 500 mg of Ciprofloxacin (oral);or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
13 A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Therapy in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis, With a Gram Negative Pathogen in Hospitalized Adults Completed NCT01595438 Phase 3 Ceftazidime - Avibactam ( CAZ-AVI);Doripenem;Either switch to oral therapy: 500 mg of Ciprofloxacin (oral);or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
14 A Multicenter, Double-blind, Randomized Study to Compare the Efficacy and Safety of Levofloxacin 750 mg Once Daily for Five Days Versus Ciprofloxacin Twice Daily for Ten Days in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis. Completed NCT00210886 Phase 3 levofloxacin
15 A Phase 3, Randomized, Multicenter, Double-Blind Study to Evaluate the Efficacy and Safety of Plazomicin Compared With Meropenem Followed by Optional Oral Therapy for the Treatment of Complicated Urinary Tract Infection (cUTI), Including Acute Pyelonephritis (AP), in Adults Completed NCT02486627 Phase 3 plazomicin;meropenem;levofloxacin (oral)
16 Phase III, Randomized, Double-Blind, Study Evaluating Efficacy/Safety/Tolerability of Meropenem-Vaborbactam Compared to Piperacillin/Tazobactam in Adult Patients With Complicated Urinary Tract Infections, Including Acute Pyelonephritis Completed NCT02166476 Phase 3 Meropenem-Vaborbactam;Piperacillin-Tazobactam;Levofloxacin;Saline
17 A Phase 3, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Cefepime-AAI101 Compared to Piperacillin/Tazobactam in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis. Completed NCT03687255 Phase 3 cefepime/AAI101 combination;Piperacillin/tazobactam
18 A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE) Completed NCT01970371 Phase 3 plazomicin;colistin;meropenem;tigecycline;antibiotic of Investigator's choice
19 Randomized, Double-Blind, Comparative Study to Evaluate the Safety and Efficacy of ZTI-01 vs Piperacillin/Tazobactam in the Treatment of cUTI/AP Infection in Hospitalized Adults Completed NCT02753946 Phase 2, Phase 3 ZTI-01;Piperacillin-tazobactam
20 A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE) Completed NCT02168946 Phase 3 Vabomere;Best Available Therapy
21 Randomized, Double-blind, Double-dummy, Active-controlled, Multi-centre Trial to Compare the Efficacy and Safety of CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) With Meropenem in Infections Caused by β-Lactamase (ESBL and MBL) Producing Gram-Negative Bacteria Completed NCT03477422 Phase 3 CSE-1034 (Ceftriaxone + Sulbactam + EDTA);Meropenem
22 A Phase 3, Randomized, Double-blind, Active Controlled Noninferiority Study Evaluating the Efficacy, Safety, and Tolerability of Cefepime/VNRX-5133 in Adults With Complicated Urinary Tract Infections (cUTI), Including Acute Pyelonephritis Recruiting NCT03840148 Phase 3 Cefepime/VNRX-5133 (taniborbactam);Meropenem
23 A Double-Blind, Randomized, Placebo-Controlled Clinical Study of the Efficacy of Intravenous Clarithromycin as Adjunctive Treatment in Patients With Sepsis and Respiratory and Multiple Organ Dysfunction Syndrome Active, not recruiting NCT03345992 Phase 3 Clarithromycin;Water for injection
24 A Phase III, Randomized, Double-Blind, Multicenter, Comparative Study to Determine the Efficacy and Safety of Cefepime-Tazobactam vs. Meropenem Followed by Optional Oral Therapy in the Treatment of Complicated Urinary Tract Infection or Acute Pyelonephritis in Adults Not yet recruiting NCT03630081 Phase 3 FEP-TAZ 4 g;Meropenem;ciprofloxacin 500 mg Optional Oral Switch
25 Randomised Controlled Trial on Efficacy and Safety of Short Term Versus Long Term Antibiotic Therapy for Pyelonephritis in Childhood. Terminated NCT00724256 Phase 3 ceftibuten;ceftibuten
26 A Randomized Controlled Trial of Sitafloxacin and Ertapenem Treatment for Acute Pyelonephritis Caused by Extended-Spectrum ß-lactamase-producing Escherichia Coli Unknown status NCT02537847 Phase 2 Sitafloxacin;Ertapenem
27 A Randomized, Double-Blinded, Adaptive Phase 2 Study to Evaluate the Safety and Efficacy of IV or IV/PO Omadacycline and IV/PO Levofloxacin in the Treatment of Adults With Acute Pyelonephritis Completed NCT03757234 Phase 2 Omadacycline;Levofloxacin
28 A Double-blind, Randomized, Comparator-controlled Study to Assess the Safety, Efficacy, and Pharmacokinetics of ACHN-490 Injection Administered IV in Patients With Complicated Urinary Tract Infections or Acute Pyelonephritis Completed NCT01096849 Phase 2 levofloxacin;plazomicin;placebo
29 Study of the Effect of Acetylcysteine on Inflammation Biomarkers in Pediatric Acute Pyelonephritis. Completed NCT02080182 Phase 2 Acetylcysteine;placebo acetylcysteine
30 A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections, Including Acute Pyelonephritis Completed NCT03445195 Phase 2 Sulbactam-ETX2514;Placebo;Imipenem-cilastatin
31 Randomized, Double-Blind, Multi-Center Study of Cefepime/AAI101 in Hospitalized Adults With Complicated Urinary Tract Infections, Including Acute Pyelonephritis Completed NCT03680612 Phase 2 Cefepime 1G - 2G / AAI101 0.5G - 0.75G;cefepime 1 g or cefepime 2 g
32 A Phase 2, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Efficacy and Safety of Intravenous Coadministered Ceftaroline Fosamil and NXL104 Versus Intravenous Doripenem in Adult Subjects With Complicated Urinary Tract Infection Completed NCT01281462 Phase 2 Ceftaroline fosamil and NXL104 (q8h);Ceftaroline fosamil and NXL104 (q12h);Doripenem;Placebo
33 A Multi-Dose, Double-Blind, Double-Dummy, Active- Control, Randomized Clinical (Phase II) Study of Two Dosing Regimens of Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis Requiring Hospitalisation. Completed NCT01928433 Phase 2 Finafloxacin 800 mg i.v. once daily;Finafloxacin placebo i.v. once daily;Finafloxacin 800 mg tablets once daily;Finafloxacin placebo tablets once daily;Ciprofloxacin 400 mg i.v. twice daily;Ciprofloxacin placebo i.v. twice daily;Ciprofloxacin 500 mg oral twice daily;Ciprofloxacin placebo oral twice daily
34 A Randomised, Double-blind, Dose-finding, Multicenter Study of the Safety, Tolerability, and Efficacy of GSK2251052 Therapy Compared to Imipenem-cilastatin in the Treatment of Adult Subjects With Febrile Complicated Lower Urinary Tract Infections and Acute Pyelonephritis Terminated NCT01381549 Phase 2 GSK2251052;imipenem-cilastatin
35 New Prognostic Classification of Acute Pyelonephritis With Adaptation of the Therapeutic. Prospective Randomized Study in the Emergency Terminated NCT01628900 Phase 2
36 Contrast-Enhanced US of Spleen, Liver and Kidney in Patients With Acute Infection (Malaria and Other Infectious Diseases: a Functional Study Unknown status NCT00190281
37 Phase 3- Dexamethasone Administration in 1st Episode of Febrile Urinary Tract Infection Episode as Renal Damage Prevention Strategy. DEXCAR Unknown status NCT02034851
38 Incidence of Post Cystography Urinary Tract Infections in the Pediatric Population Unknown status NCT03399682
39 Urinary Cytokine Levels as a Prognostic Marker for Kidney Scarring After Pyelonephritis Unknown status NCT00868270
40 Quantitating Proteinuria During Acute Pyelonephritis In Pregnancy Unknown status NCT02536638
41 Kinetics of Procalcitonin, C-reactive Protein and Pyuria in Uncomplicated Pyelonephritis in Women: A Pilot Study Completed NCT00805181
42 Surveillance and Risk Factor Analysis of Community-Associated Uropathogen Antimicrobial Resistance Among Emergency Department Patients With Acute Pyelonephritis in the United States Completed NCT01641029
43 Effect of Systematic Search and Antimicrobial Treatment of Asymptomatic Bacteriuria in Kidney Transplant Recipients in the Incidence of Acute Pyelonephritis: a Pragmatic Prospective Randomized Controlled Study. Completed NCT02373085
44 Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae Completed NCT02420366
45 Non-invasive Blood Test to Diagnose Acute Rejection After Pancreas and Kidney Transplantation: Pancreas and Renal Rejection Diagnosis Using Circulating Donor-derived Cell-free DNA in Peripheral Blood Recruiting NCT04166149
46 Distribution of Virulence Genes and Their Association With Clinical Presentation of Urinary Tract Infection and Antimicrobial Resistance Among Uropathogenic Escherichia Coli Isolated From Pregnant Women Not yet recruiting NCT04244526
47 The Validity of the Quick Renal MRI in Pediatric Kidney Disease Suspended NCT03959163
48 Efficacy and Pharmacokinetic/Pharmacodynamic Parameters of Cefoxitin in Women With Acute Pyelonephritis Without Severity Symptoms Due to Extended-spectrum β-lactamase Producing Escherichia Coli. Terminated NCT01820793 Cefoxitin
49 Bacterial and Host Genetic Risk Factors That Predispose Children to Acute Pyelonephritis and Renal Scarring Withdrawn NCT01137929

Search NIH Clinical Center for Acute Pyelonephritis

Sources

Genetic Tests for Acute Pyelonephritis

About this section
Sources

Anatomical Context for Acute Pyelonephritis

About this section

MalaCards organs/tissues related to Acute Pyelonephritis:

40
Kidney, Testes, Neutrophil, Liver, Prostate, Colon, Spleen
Sources

Publications for Acute Pyelonephritis

About this section

Articles related to Acute Pyelonephritis:

(show top 50) (show all 2315)
# Title Authors PMID Year
1
Clinical implication of serum C-reactive protein in patients with uncomplicated acute pyelonephritis as marker of prolonged hospitalization and recurrence. 61 54
18930516 2009
2
Urinary N-acetyl-beta-D-glucosaminidase as a diagnostic marker of acute pyelonephritis in children. 61 54
19367005 2008
3
Urine interleukin-1beta in children with acute pyelonephritis and renal scarring. 61 54
17803473 2007
4
A genetic basis of susceptibility to acute pyelonephritis. 61 54
17786197 2007
5
Serum and urine levels of interleukin-6 and interleukin-8 in children with acute pyelonephritis. 54 61
17374489 2006
6
Expression of interleukin-8 receptors (CXCR1 and CXCR2) in premenopausal women with recurrent urinary tract infections. 61 54
16339057 2005
7
Chemokine response to febrile urinary tract infection. 54 61
15954896 2005
8
[Assessment of fructose-1,6-biphosphatase in urine of children with acute pyelonephritis]. 61 54
15074024 2004
9
Serum amyloid A: a novel serum marker for the detection of systemic inflammatory response in cystitis. 61 54
12913703 2003
10
Neutrophil recruitment, chemokine receptors, and resistance to mucosal infection. 54 61
11404374 2001
11
Symptomatic urinary tract infection in women in primary health care. Bacteriological, clinical and diagnostic aspects in relation to host response to infection. 61 54
8792507 1996
12
Functional parameters and 99mtechnetium-dimercaptosuccinic acid scan in acute pyelonephritis. 61 54
7696107 1994
13
Renal scarring after acute pyelonephritis. 54 61
8129430 1994
14
[NAG (N-acetyl-beta-D-glucosaminidase)--a sensitive marker for disorders of kidney function]. 54 61
2316078 1990
15
Diabetes mellitus increases mortality in acute pyelonephritis patients: a population study based on the National Health Insurance Claim Data of South Korea for 2010-2014. 61
32301098 2020
16
Commentary to 'Diffusion weighted imaging is a promising method to detect acute pyelonephritis in non-sedated free breathing infants'. 61
32456875 2020
17
Diffusion weighted imaging is a promising method to detect acute pyelonephritis in non-sedated free breathing infants. 61
32336597 2020
18
Lack of Impact of Acute Pyelonephritis on Kidney Graft Survival. 61
32197868 2020
19
Oral treatment of acute pyelonephritis: when, with which antimicrobial agent and for how long? 61
32536596 2020
20
Relationship between low serum vitamin D status and urinary tract infection in children: a case-control study. 61
32490740 2020
21
[Urinary tract infections in adults: Comparison of the French and the European guidelines]. 61
32418735 2020
22
CT imaging of acute and chronic pyelonephritis: a practical guide for emergency radiologists. 61
32445022 2020
23
Scrub typhus as a rare cause of acute pyelonephritis: case report. 61
32375669 2020
24
Urinary tract infections in children. 61
32446408 2020
25
Clinical Characteristics of Pediatric Pyelonephritis Without Pyuria or Bacteriuria. 61
32187138 2020
26
Preventive Effect of L-Carnitine on Scar Formation During Acute Pyelonephritis: A Randomized Placebo-Controlled Trial. 61
30418227 2020
27
Molecular Epidemiology of Ciprofloxacin-Resistant Escherichia coli Isolated from Community-Acquired Urinary Tract Infections in Korea. 61
32406212 2020
28
In vitro activity of omadacycline and levofloxacin against Escherichia coli, Klebsiella pneumoniae and Staphylococcus saprophyticus in human urine supplemented with calcium and magnesium. 61
32428235 2020
29
Pharmacokinetics-Pharmacodynamics of Enmetazobactam Combined with Cefepime in a Neutropenic Murine Thigh Infection Model. 61
32253212 2020
30
Novel β-Lactam/β-Lactamase inhibitor combinations vs alternative antibiotics in the treatment of complicated urinary tract infections: A meta-analysis of randomized controlled trials. 61
32384444 2020
31
The C5a/C5aR2 axis promotes renal inflammation and tissue damage. 61
32191644 2020
32
The use of plasma donor-derived, cell-free DNA to monitor acute rejection after kidney transplantation. 61
31106364 2020
33
Comparison of Cohen and Lich-Gregoir ureteral reimplantation in the surgical management of primary unilateral vesicoureteral reflux in children. 61
32578774 2020
34
Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study. 61
32239659 2020
35
Novel Coronavirus (2019-nCoV) in Disguise. 61
32377469 2020
36
An Update on Existing and Emerging Data for Meropenem-Vaborbactam. 61
32147146 2020
37
Current status of imaging diagnosis in the transplanted kidney. A review of the literature with a special focus on contrast-enhanced ultrasonography. 61
32478319 2020
38
[Methods of the videoendoscopic correction of the ureters strictures]. 61
32351062 2020
39
[Predictive markers of acute focal bacterial nephritis. A multicentre case-control study]. 61
32205055 2020
40
Presepsin and procalcitonin as predictors of sepsis based on the new Sepsis-3 definitions in obstructive acute pyelonephritis. 61
32160878 2020
41
Comparison of imaging findings between acute focal bacterial nephritis (acute lobar nephronia) and acute pyelonephritis: a preliminary evaluation of the sufficiency of ultrasound for the diagnosis of acute focal bacterial nephritis. 61
32162084 2020
42
Urinary tract infection in pediatrics: an overview. 61
31783012 2020
43
Postoperative Progress after Stone Removal Following Treatment for Obstructive Acute Pyelonephritis Associated with Urinary Tract Calculi: A Retrospective Study. 61
31328250 2020
44
Efficacy and Safety of Sitafloxacin in the Treatment of Acute Bacterial Infection: A Meta-analysis of Randomized Controlled Trials. 61
32131414 2020
45
Associations of Plasma Neutrophil Gelatinase-associated Lipocalin, Anemia, and Renal Scarring in Children with Febrile Urinary Tract Infections. 61
32174064 2020
46
A Case of a False-Positive Urine Pregnancy Test and Delayed Diagnosis of Obstructive Pyelonephritis. 61
32210220 2020
47
Urinary carbohydrate antigen 19-9 level as a biomarker in children with acute pyelonephritis. 61
32146571 2020
48
Relationship between Breastfeeding, Birth History, and Acute Pyelonephritis in Infants. 61
32103642 2020
49
[Immune system disorders in acute pyelonephritis. II art]. 61
32191012 2020
50
Management of acute pyelonephritis in the emergency department observation unit. 61
32147739 2020
Sources

Variations for Acute Pyelonephritis

About this section
Sources

Expression for Acute Pyelonephritis

About this section
Search GEO for disease gene expression data for Acute Pyelonephritis.
Sources

Pathways for Acute Pyelonephritis

About this section

Pathways related to Acute Pyelonephritis according to GeneCards Suite gene sharing:

(show all 38)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14.01 LCN2 IL6 IL1A IL10 IFNG CXCR2
2
ERK Signaling 63
Show member pathways
 13.79 PGF IL6 IL1A IL10 CXCR2 CXCR1
3
PEDF Induced Signaling 63
Show member pathways
 13.64 IL6 IL1A IL10 IFNG CXCR2 CXCR1
4
Akt Signaling 63
Show member pathways
 13.35 PGF IL6 IL1A IL10 CXCR2 CXCR1
5
Cytokine Signaling in Immune system 65
Show member pathways
 13.31 LCN2 IL6 IL1A IL10 IFNG CXCL8
6
PAK Pathway 63
Show member pathways
 13.18 PGF IL6 IL1A IL10 CXCR2 CXCR1
7
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.01 IL6 IL10 IFNG CXCL8 CXCL10 ACE
8
Allograft rejection 1 36
Show member pathways
 12.81 IL6 IL1A IL10 IFNG CXCL8
9
Measles 36
Show member pathways
 12.77 IL6 IL1A IFNG CXCL8 CXCL10
10
Folate Metabolism 1
Show member pathways
 12.29 IL6 IFNG CRP ALB
11
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.21 PGF IL6 IL1A IL10 IFNG CXCL8
12
Tuberculosis 36
12.19 IL6 IL1A IL10 IFNG
13
Bacterial infections in CF airways 22
Show member pathways
 12.15 IL6 IFNG CXCL8 CXCL10
14
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.13 IL6 IL1A IL10 CXCL8
15
IL-17 Family Signaling Pathways 64
Show member pathways
 12.13 LCN2 IL6 IFNG CXCL8 CXCL10 CSF3
16
Chemokine Superfamily: Human/Mouse Ligand-Receptor Interactions 64
Show member pathways
 12.07 IL6 IL10 CXCR2 CXCR1 CXCL8 CXCL10
17
Hematopoietic Stem Cells and Lineage-specific Markers 64
11.96 IL6 IL10 IFNG CSF3
18
Senescence and Autophagy in Cancer 1
11.91 IL6 IL1A IFNG CXCL8
19
Amoebiasis 36
11.89 IL6 IL10 IFNG CXCL8
20
Spinal Cord Injury 1
11.88 IL6 IL1A IFNG CXCL8 CXCL10
21
Rheumatoid arthritis 36
11.84 IL6 IL1A IFNG CXCL8
22
Interleukin-4 and 13 signaling 65
11.82 LCN2 IL6 IL1A IL10 CXCL8
23
Glucocorticoid receptor regulatory network 1
11.76 IL6 IFNG CXCL8
24
Pertussis 36
11.72 IL6 IL1A IL10 CXCL8
25
Dendritic Cells Developmental Lineage Pathway 64
11.7 IL6 IL10 IFNG
26
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.61 IL6 IL1A IFNG CXCL8
27
Lung fibrosis 1
11.6 IL6 CXCL8 CSF3 CALCA
28
ATF-2 transcription factor network 1
11.56 IL6 IFNG CXCL8
29
Hepatitis C and Hepatocellular Carcinoma 1
11.52 IL6 CXCR1 CXCL8
30
Hematopoietic Stem Cell Differentiation 1
11.48 IL6 IL1A CSF3
31
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
11.39 IL6 IL1A IFNG CALCA
32
African trypanosomiasis 36
11.36 IL6 IL10 IFNG
33
IL-10 Pathway 63
11.33 IL6 IL1A IL10
34
Malaria 36
11.25 IL6 IL10 IFNG CXCL8 CSF3
35
Overview of nanoparticle effects 1
11.01 IL6 CXCL8 CRP
36
G-protein signaling_Rap2B regulation pathway 22
10.92 PGF IL6 IL1A IL10 CXCL8 CXCL10
37
Cytokines and Inflammatory Response 1
10.82 IL6 IL1A IL10 IFNG CSF3
38
Interleukin-10 signaling 65
10.79 IL6 IL1A IL10 CXCL8 CXCL10 CSF3
Sources

GO Terms for Acute Pyelonephritis

About this section

Cellular components related to Acute Pyelonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.86 PGF NAMPT LCN2 IL6 IL1A IL10
2 cell GO:0005623 9.7 LCN2 IL6 CXCR2 CXCR1 CXCL10 CALCA
3 extracellular space GO:0005615 9.53 PGF NAMPT LCN2 IL6 IL1A IL10

Biological processes related to Acute Pyelonephritis according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.19 PGF NAMPT IL6 IL10 CXCR2 CXCR1
2 positive regulation of gene expression GO:0010628 10.02 LCN2 IL6 IL1A IFNG CRP
3 negative regulation of cell proliferation GO:0008285 10 IL6 IL1A IL10 CXCL8 ADM
4 cell-cell signaling GO:0007267 9.93 PGF NAMPT CXCL10 CALCA
5 inflammatory response GO:0006954 9.92 IL6 IL1A CXCR2 CXCL8 CXCL10 CRP
6 cytokine-mediated signaling pathway GO:0019221 9.91 LCN2 IL6 IL1A IL10 CXCL8 CXCL10
7 aging GO:0007568 9.87 NAMPT IL10 CALCA ADM
8 chemotaxis GO:0006935 9.86 CXCR2 CXCR1 CXCL8 CXCL10
9 positive regulation of cytosolic calcium ion concentration GO:0007204 9.85 CXCR2 CXCR1 CALCA ADM
10 positive regulation of cell proliferation GO:0008284 9.81 PGF NAMPT IL6 IFNG ESM1 CXCR2
11 positive regulation of angiogenesis GO:0045766 9.8 PGF IL1A CXCR2 CXCL8 ADM
12 neutrophil chemotaxis GO:0030593 9.78 CXCR2 CXCR1 CXCL8 CXCL10
13 response to glucocorticoid GO:0051384 9.77 IL6 IL10 ADM
14 chemokine-mediated signaling pathway GO:0070098 9.76 CXCR2 CXCR1 CXCL8 CXCL10
15 positive regulation of cytokine secretion GO:0050715 9.71 IL1A IL10 IFNG
16 leukocyte chemotaxis GO:0030595 9.69 IL10 CXCL8 CXCL10
17 receptor internalization GO:0031623 9.65 CXCR2 CXCR1 CXCL8 CALCA ADM
18 response to molecule of bacterial origin GO:0002237 9.63 IL10 CXCL8
19 positive regulation of MHC class II biosynthetic process GO:0045348 9.62 IL10 IFNG
20 negative regulation of lipid storage GO:0010888 9.61 IL6 CRP
21 branching involved in labyrinthine layer morphogenesis GO:0060670 9.61 IL10 ADM
22 positive regulation of leukocyte chemotaxis GO:0002690 9.61 IL6 CXCR2 CXCL10
23 neutrophil mediated immunity GO:0002446 9.58 IL6 ACE
24 amylin receptor signaling pathway GO:0097647 9.58 CALCA ADM
25 interleukin-8-mediated signaling pathway GO:0038112 9.52 CXCR2 CXCR1
26 cellular response to lipopolysaccharide GO:0071222 9.5 LCN2 IL6 IL1A IL10 CXCL8 CXCL10
27 immune response GO:0006955 9.28 IL6 IL1A IL10 IFNG CXCR2 CXCR1

Molecular functions related to Acute Pyelonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.62 PGF IL6 IL10 CSF3
2 drug binding GO:0008144 9.58 NAMPT ALB ACE
3 C-X-C chemokine receptor activity GO:0016494 9.37 CXCR2 CXCR1
4 interleukin-8 binding GO:0019959 9.26 CXCR2 CXCR1
5 cytokine activity GO:0005125 9.23 NAMPT IL6 IL1A IL10 IFNG CXCL8
6 enterobactin binding GO:1903981 9.16 LCN2 ALB
7 interleukin-8 receptor activity GO:0004918 8.96 CXCR2 CXCR1
Sources

Sources for Acute Pyelonephritis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....